Seizure Recurrence after GLP-1 Receptor Agonist Initiation in Adults with Epilepsy

In a recent study, researchers investigated whether starting a glucagon-like peptide-1 receptor agonist (GLP-1 RA), like Ozempic or Wegovy, is associated with lower seizure recurrence and related outcomes in adults with both epilepsy and type 2 diabetes.

The study utilized de-identified electronic health records from adults 18 years or older with recurrent seizures. New users of GLP-1 RAs were compared with new users of other glucose-lowering drugs. The study found that GLP-1 RA initiation was associated with an 18% lower risk of recurrent seizures, as well as substantially lower inpatient hospitalization rates and mortality. GLP-1 RA therapy was also associated with improved clinical outcomes compared with other glucose-lowering agents.

These associations align with preclinical evidence that GLP-1 signaling has neuroprotective and anti-inflammatory effects that could reduce seizure susceptibility. More research—especially clinical trials—is needed before these medicines can be recommended for seizure control.

Learn More